UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evaluation of Methods to Assess CYP3A Induction Risk in Clinical Practice Using in Vitro Induction Parameters

Biological and Pharmaceutical Bulletin, 2021/03/01, Vol.44(3), pp.338-349

2021

Volltextzugriff (PDF)

Quantitative prediction of CYP3A induction-mediated drug-drug interactions in clinical practice

Drug metabolism and pharmacokinetics, 2024-08, Vol.57, p.101010, Article 101010

2024

Volltextzugriff (PDF)

Validation of a New Methodology to Create Oral Drugs beyond the Rule of 5 for Intracellular Tough Targets

Journal of the American Chemical Society, 2023-11, Vol.145 (44), p.24035-24051

2023

Volltextzugriff (PDF)

Quantitative evaluation of hepatic and intestinal induction of CYP3A in clinical practice

Xenobiotica, 2020-08, Vol.50 (8), p.875-884

2020

Volltextzugriff (PDF)

Quantitative prediction of CYP3A4 Induction using simple relative factor approach

Drug metabolism and pharmacokinetics, 2019-01, Vol.34 (1), p.S42-S43

2019

Volltextzugriff (PDF)

Risk of CYP2C9 induction analyzed by a relative factor approach with human hepatocytes

Drug metabolism and pharmacokinetics, 2019-10, Vol.34 (5), p.325-333

2019

Volltextzugriff (PDF)

Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799

Bioorganic & medicinal chemistry letters, 2011-03, Vol.21 (6), p.1767-1772

2011

Volltextzugriff (PDF)

Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats

The Journal of Toxicological Sciences, 2014/04/01, Vol.39(2), pp.237-242

2014

Volltextzugriff (PDF)

Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor

Journal of the American Chemical Society, 2023-08, Vol.145 (30), p.16610-16620

2023

Volltextzugriff (PDF)

Prediction of drug-induced QT interval prolongation in telemetered common marmosets

The Journal of Toxicological Sciences, 2008/08/01, Vol.33(3), pp.315-325

2008

Volltextzugriff (PDF)

Simple Evaluation Method for CYP3A4 Induction from Human Hepatocytes: The Relative Factor Approach with an Induction Detection Limit Concentration Based on the Emax Model

Drug metabolism and disposition, 2017-11, Vol.45 (11), p.1139-1145

2017

Volltextzugriff (PDF)

Simple Evaluation Method for CYP3A4 Induction from Human Hepatocytes: The Relative Factor Approach with an Induction Detection Limit Concentration Based on the E max Model

Drug metabolism and disposition, 2017-11, Vol.45 (11), p.1139-1145

2017

Volltextzugriff (PDF)

Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor

Journal of medicinal chemistry, 2022-09, Vol.65 (18), p.12427-12444

2022

Volltextzugriff (PDF)

Structure-activity relationships of middle-size cyclic peptides, KRAS inhibitors derived from an mRNA display

Bioorganic & medicinal chemistry, 2024-08, Vol.110, p.117830, Article 117830

2024

Volltextzugriff (PDF)

Simple Evaluation Method for CYP3A4 Induction from Human Hepatocytes: The Relative Factor Approach with an Induction Detection Limit Concentration Based on the E^sub max^ Model

Drug metabolism and disposition, 2017-11, Vol.45 (11), p.1139

2017

Volltextzugriff (PDF)

The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations

Clinical cancer research, 2011-05, Vol.17 (10), p.3272-3281

2011

Volltextzugriff (PDF)

Abstract 1664: Combination of LUNA18, a novel RAS inhibitor, with KRAS G12C inhibitors augments anti-tumor activity via inhibition of MAPK pathway reactivation

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.1664-1664

2024

Volltextzugriff (PDF)

Stereoselectivity in the oxidation of bufuralol, a chiral substrate, by human cytochrome P450s

Chirality (New York, N.Y.), 2003, Vol.15 (4), p.333-339

2003

Volltextzugriff (PDF)

Abstract 1654: Anti-tumor activity of orally-available cyclic peptide LUNA18 through direct RAS inhibition in RAS-altered tumors

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.1654-1654

2024

Volltextzugriff (PDF)

Angiogenesis inhibitors identified by cell-based high-throughput screening: Synthesis, structure–activity relationships and biological evaluation of 3-[(E)-styryl]benzamides that specifically inhibit endothelial cell proliferation

Bioorganic & medicinal chemistry, 2012-02, Vol.20 (4), p.1442-1460

2012

Volltextzugriff (PDF)

Cloning and functional expression of a novel marmoset cytochrome P450 2D enzyme, CYP2D30: comparison with the known marmoset CYP2D19

Biochemical pharmacology, 2004-07, Vol.68 (1), p.165-175

2004

Volltextzugriff (PDF)

Cloning and functional expression of a novel marmoset cytochrome P450 2D enzyme, CYPD30: comparison with the known marmoset CYP2D19

Biochemical pharmacology, 2004, Vol.68 (1), p.165-175

2004

Volltextzugriff (PDF)

Photocatalytic Fluidized Bed System for NOx Removal from Exhaust Gas

Kagaku kōgaku ronbunshū, 2004-05, Vol.30 (3), p.285-291

2004

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(23)

Sprache

Englisch
(22)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evaluation of Methods to Assess CYP3A Induction Risk in Clinical Practice Using in Vitro Induction Parameters

Quantitative prediction of CYP3A induction-mediated drug-drug interactions in clinical practice

Validation of a New Methodology to Create Oral Drugs beyond the Rule of 5 for Intracellular Tough Targets

Quantitative evaluation of hepatic and intestinal induction of CYP3A in clinical practice

Quantitative prediction of CYP3A4 Induction using simple relative factor approach

Risk of CYP2C9 induction analyzed by a relative factor approach with human hepatocytes

Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799

Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats

Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor

Prediction of drug-induced QT interval prolongation in telemetered common marmosets

Simple Evaluation Method for CYP3A4 Induction from Human Hepatocytes: The Relative Factor Approach with an Induction Detection Limit Concentration Based on the Emax Model

Simple Evaluation Method for CYP3A4 Induction from Human Hepatocytes: The Relative Factor Approach with an Induction Detection Limit Concentration Based on the E max Model

Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor

Structure-activity relationships of middle-size cyclic peptides, KRAS inhibitors derived from an mRNA display

Simple Evaluation Method for CYP3A4 Induction from Human Hepatocytes: The Relative Factor Approach with an Induction Detection Limit Concentration Based on the E^sub max^ Model

The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations

Abstract 1664: Combination of LUNA18, a novel RAS inhibitor, with KRAS G12C inhibitors augments anti-tumor activity via inhibition of MAPK pathway reactivation

Stereoselectivity in the oxidation of bufuralol, a chiral substrate, by human cytochrome P450s

Abstract 1654: Anti-tumor activity of orally-available cyclic peptide LUNA18 through direct RAS inhibition in RAS-altered tumors

Angiogenesis inhibitors identified by cell-based high-throughput screening: Synthesis, structure–activity relationships and biological evaluation of 3-[(E)-styryl]benzamides that specifically inhibit endothelial cell proliferation

Cloning and functional expression of a novel marmoset cytochrome P450 2D enzyme, CYP2D30: comparison with the known marmoset CYP2D19

Cloning and functional expression of a novel marmoset cytochrome P450 2D enzyme, CYPD30: comparison with the known marmoset CYP2D19

Photocatalytic Fluidized Bed System for NOx Removal from Exhaust Gas

Suchergebnisse filtern